Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects - PubMed (original) (raw)
Clinical Trial
Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
Xuemin Jiang et al. Br J Clin Pharmacol. 2005 Apr.
Abstract
Aim: The aim of this study was to investigate the effect of two common herbal medicines, ginkgo and ginger, on the pharmacokinetics and pharmacodynamics of warfarin and the independent effect of these herbs on clotting status.
Methods: This was an open label, three-way crossover randomized study in 12 healthy male subjects, who received a single 25 mg dose of warfarin alone or after 7 days pretreatment with recommended doses of ginkgo or ginger from herbal medicine products of known quality. Dosing with ginkgo or ginger was continued for 7 days after administration of the warfarin dose. Platelet aggregation, international normalized ratio (INR) of prothrombin time, warfarin enantiomer protein binding, warfarin enantiomer concentrations in plasma and S-7-hydroxywarfarin concentration in urine were measured. Statistical comparisons were made using anova and the 90% confidence intervals (CIs) of the ratio of log transformed parameters are reported.
Results: INR and platelet aggregation were not affected by administration of ginkgo or ginger alone. The mean (95% CI) apparent clearances of S-warfarin after warfarin alone, with ginkgo or ginger were 189 (167-210) ml h(-1), 200 (173-227) ml h(-1) and 201 (171-231) ml h(-1), respectively. The respective apparent clearances of R-warfarin were 127 (106-149) ml h(-1), 126 (111-141) ml h(-1) and 131 (106-156) ml h(-1). The mean ratio (90% CI) of apparent clearance for S-warfarin was 1.05 (0.98-1.21) and for R-warfarin was 1.00 (0.93-1.08) when coadministered with ginkgo. The mean ratio (90% CI) of AUC(0-168) of INR was 0.93 (0.81-1.05) when coadministered with ginkgo. The mean ratio (90% CI) of apparent clearance for S-warfarin was 1.05 (0.97-1.13) and for R-warfarin was 1.02 (0.95-1.10) when coadministered with ginger. The mean ratio (90% CI) of AUC(0-168) of INR was 1.01 (0.93-1.15) when coadministered with ginger. The mean ratio (90% CI) for S-7-hydroxywarfarin urinary excretion rate was 1.07 (0.85-1.32) for ginkgo treatment, and 1.00 (0.81-1.23) for ginger coadministration suggesting these herbs did not affect CYP2C9 activity. Ginkgo and ginger did not affect the apparent volumes of distribution or protein binding of either S-warfarin or R-warfarin.
Conclusions: Ginkgo and ginger at recommended doses do not significantly affect clotting status, the pharmacokinetics or pharmacodynamics of warfarin in healthy subjects.
Figures
Figure 1
(S) warfarin log concentration-time profiles following a single oral 25 mg _rac_-warfarin dose alone (▪), coadministered with ginkgo (warfarin + ginkgo) (♦), or ginger (▵), (Mean ± SD, n = 12) in healthy male subjects
Figure 2
(R) warfarin log concentration-time profiles following a single oral 25 mg _rac_-warfarin dose alone (▪), coadministered with ginkgo (warfarin + ginkgo) (♦), or ginger (▵), (Mean ± SD, n = 12) in healthy male subjects
Figure 3
INR-time profiles following a single oral 25 mg _rac_-warfarin dose alone (□), combination with ginkgo (warfarin + ginkgo) (▴) or ginger (warfarin + ginger) (♦) (Mean ± SD, n = 12, warfarin dose administered at time 0)
Similar articles
- Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Jiang X, et al. Br J Clin Pharmacol. 2004 May;57(5):592-9. doi: 10.1111/j.1365-2125.2003.02051.x. Br J Clin Pharmacol. 2004. PMID: 15089812 Free PMC article. Clinical Trial. - Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach.
Jiang X, Blair EY, McLachlan AJ. Jiang X, et al. J Clin Pharmacol. 2006 Nov;46(11):1370-8. doi: 10.1177/0091270006292124. J Clin Pharmacol. 2006. PMID: 17050802 Clinical Trial. - Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects.
Mohammed Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, McLachlan AJ. Mohammed Abdul MI, et al. Br J Pharmacol. 2008 Aug;154(8):1691-700. doi: 10.1038/bjp.2008.210. Epub 2008 Jun 2. Br J Pharmacol. 2008. PMID: 18516070 Free PMC article. Clinical Trial. - Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence.
Vaes LP, Chyka PA. Vaes LP, et al. Ann Pharmacother. 2000 Dec;34(12):1478-82. doi: 10.1345/aph.10031. Ann Pharmacother. 2000. PMID: 11144706 Review. - Clinical herbal interactions with conventional drugs: from molecules to maladies.
Chen XW, Serag ES, Sneed KB, Liang J, Chew H, Pan SY, Zhou SF. Chen XW, et al. Curr Med Chem. 2011;18(31):4836-50. doi: 10.2174/092986711797535317. Curr Med Chem. 2011. PMID: 21919844 Review.
Cited by
- Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management.
Zhang XL, Chen M, Zhu LL, Zhou Q. Zhang XL, et al. Evid Based Complement Alternat Med. 2017;2017:9296404. doi: 10.1155/2017/9296404. Epub 2017 Apr 11. Evid Based Complement Alternat Med. 2017. PMID: 28491115 Free PMC article. Review. - Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Ageno W, et al. Chest. 2012 Feb;141(2 Suppl):e44S-e88S. doi: 10.1378/chest.11-2292. Chest. 2012. PMID: 22315269 Free PMC article. Review. - Ginger in gastrointestinal disorders: A systematic review of clinical trials.
Nikkhah Bodagh M, Maleki I, Hekmatdoost A. Nikkhah Bodagh M, et al. Food Sci Nutr. 2018 Nov 5;7(1):96-108. doi: 10.1002/fsn3.807. eCollection 2019 Jan. Food Sci Nutr. 2018. PMID: 30680163 Free PMC article. Review. - Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies.
Qiu JX, Zhou ZW, He ZX, Zhang X, Zhou SF, Zhu S. Qiu JX, et al. Drug Des Devel Ther. 2015 Feb 16;9:841-66. doi: 10.2147/DDDT.S74669. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25733806 Free PMC article. - Drug interactions with herbal medicines.
Shi S, Klotz U. Shi S, et al. Clin Pharmacokinet. 2012 Feb 1;51(2):77-104. doi: 10.2165/11597910-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22257149 Review.
References
- Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother. 2000;34:1478–82. - PubMed
- Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2002;4:CD003120. - PubMed
- McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med. 2001;7:70–86. 88–90. - PubMed
- Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002;71:1579–89. - PubMed
- Shinozuka K, Umegaki K, Kubota Y, Tanaka N, Mizuno H, Yamauchi J, et al. Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci. 2002;70:2783–92. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical